Perspective continues to pursue dose escalation of 212PbVMT-alpha-NET

Perspective Therapeutics (CATX) announced updated interim results from its ongoing Phase 1/2a clinical trial of 212PbVMT-alpha-NET that are being presented as a poster presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, ASCO-GI, taking place January 23-25, 2025 in San Francisco, CA. This Phase 1/2a clinical trial is a multi-center open-label dose escalation and dose expansion study of 212PbVMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors who have not received prior radiopharmaceutical therapy and whose tumors have shown radiological evidence of disease progression in the 12 months prior to enrollment. 212PbVMT-alpha-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested; Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response; The five other patients in Cohorts 1 and 2 who previously experienced stable disease remain in stable disease